Abstract: A monitoring system includes a non-transitory computer readable medium configured to store instructions; and a processor. The processor is configured to execute the instructions for retrieving performance data from a performance network register (PNR) for each of a plurality of servers, wherein the servers are configured to implement a functionality of the system, and retrieving the performance data includes avoiding directly accessing the servers. The processor is configured to execute the instructions for storing the received performance data for each server in association with identification information for a corresponding server. The processor is configured to execute the instructions for receiving parameters for generating a display of monitored data. The processor is further configured to execute the instructions for accessing the stored performance data to generate the display of monitored data; and transmitting the display of monitored data to at least one operator system.

Abstract: The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of chlamydia infection and/or the effects thereof.

Abstract: The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of chlamydia infection and/or the effects thereof.

Abstract: The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of chlamydia infection and/or the effects thereof.

Abstract: The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of chlamydia infection and/or the effects thereof.

Abstract: A pharmaceutical composition comprising bisacodyl [4,4?-(pyridine-2-ylmethylene)bis(4,1-phenylene) diacetate], a solvent, a buffer, and a polymer, methods and apparatus for delivery to a patient.

Abstract: A ball pickup device is provided, comprising a ball collector and a pull rod connected to the ball connector. The ball collector has ball inlets formed at the bottom of the ball collector and formed by transverse rods arranged at the bottom of the ball collector in parallel at intervals, and one ball outlet is formed by the interval between every two adjacent transverse rods. Each interval is smaller than the diameter of a ball. One end of each transverse rod is fixedly connected to the ball collector, and the other end is a movable end and located in the corresponding receding groove. When a ball is pressed, movable ends move along receding grooves to recede under the pressure of the ball, and the ball enters the ball collector. After the ball enters the ball inlet, movable ends move along receding grooves to gradually return.

Abstract: A ball pickup device is provided, comprising a ball collector and a pull rod connected to the ball connector. The ball collector has ball inlets formed at the bottom of the ball collector and formed by transverse rods arranged at the bottom of the ball collector in parallel at intervals, and one ball outlet is formed by the interval between every two adjacent transverse rods. Each interval is smaller than the diameter of a ball. One end of each transverse rod is fixedly connected to the ball collector, and the other end is a movable end and located in the corresponding receding groove. When a ball is pressed, movable ends move along receding gooves to recede under the pressure of the ball, and the ball enters the ball collector. After the ball enters the ball inlet, movable ends move along receding grooves to gradually return.

Abstract: A pharmaceutical composition comprising bisacodyl [4,4?-(pyridine-2-ylmethylene)bis(4,1-phenylene) diacetate], a solvent, a buffer, and a polymer, methods and apparatus for delivery to a patient.

Abstract: A pharmaceutical composition for the treatment of hemorrhoids, sheets, methods of making and using the same.

Abstract: A composition for treating and preventing diaper rash comprises zinc oxide, dimethicone, mineral oil, a suspending agent, and an emulsifier. The emulsifier has a Hydrophile-Lipophile Balance number of at most 4.5 and the composition is sprayable. The suspending agent may be a hydrophobic clay.

Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.

Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.

Abstract: The present invention provides genetic markers and biomarkers that are associated with anemia induced by ribavirin therapy. The genetic markers are located in the ITPA gene and elsewhere on human chromosome 20 and the biomarkers are low ITPA activity phenotypes. These markers of ribavirin-induced anemia are useful, inter alia, to identify patients who are least likely to develop anemia upon treatment with ribavirin pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with ribavirin, and in methods for selecting the most appropriate therapy for such patients.

Abstract: An inductor circuit with high quality (Q) factor includes a primary inductor and a compensation sub-circuit. The compensation sub-circuit is electrically isolated from the primary inductor. The compensation sub-circuit is magnetically coupled with the primary inductor to compensate the loss in the primary inductor.

Abstract: A processing method for group resource allocation comprises that: a base station establishes groups according to modulation and coding schemes and/or resource sizes (202), the modulation and coding schemes and/or resource sizes supported by the groups are static or quasi-static (204). With the present invention, the groups can be established based on modulation and coding schemes and/or resource sizes, and the modulation and coding schemes and/or resource sizes of the groups can be changed, compared with the prior art, the complexity of the group resource allocation method in the wireless communication system and the control overhead can be reduced, and the transmission bandwidth utilization of the wireless communication system can be improved.

Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers arc useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.

Abstract: An inductor circuit with high quality (Q) factor includes a primary inductor and a compensation sub-circuit. The compensation sub-circuit is electrically isolated from the primary inductor. The compensation sub-circuit is magnetically coupled with the primary inductor to compensate the loss in the primary inductor.

Abstract: A method and apparatus adapted to calibrate a signal path of a signal analysis system such that digital samples of a signal under test acquired by the system are processed for representing the impedance of a device under test. The method and apparatus calibrates the signal path to characterize transfer parameters of the device under test within a spectral domain. A reference impedance (Zref) is retrieved that is associated with the signal analysis system. The transfer parameters of the device under test and the reference impedance (Zref) are processed to effect thereby a representation of the device under test impedance (Zeq) as a function of frequency.

Abstract: The present invention relates to a method for developing algorithms that are capable of discriminating among different genotypes and subtypes of a virus of interest. The method includes aligning a set of viral nucleotide sequences having known genotypes and analyzing the aligned sequences to identify nucleotide positions at which the nucleotide is conserved within genotypes, but diversified across the different known genotypes. These positions, referred to herein as genotyping positions, are employed as predictive variables to compile a variable input table for analysis by a statistical classification algorithm. The variable input table also includes the nucleotide present at each genotyping position as a value and the genotype for each of the aligned sequences as a response variable.